Sort
10,766 grants matching “checkpoint inhibitor”
Targeting Cell Cycle Checkpoints in Cancer Therapeutics
$105,684Archie N Tse · Sloan-Kettering Inst Can Research · K08 · FY2009 · CA
Musculoskeletal Pain Among Breast Cancer Survivors: Through Bio-behavioral and Imaging Lenses
$105,589Yehui Zhu · Massachusetts General Hospital · K00 · FY2023 · CA
Effects of FLASH Radiation on Cancer and the Immune Response
$105,129Edgar G. Engleman · Stanford University · R01 · FY2022 · CA
Consolidated Basic Cancer Research Program
$104,776Dario C. Altieri · Wistar Institute · P30 · FY2020 · CA
Parametric optimization of ultrasound-mediated immuno-modulation for pancreatic cancer therapy
$104,640Paul A Dayton · Univ Of North Carolina Chapel Hill · R21 · FY2022 · CA
Exploring the potential of TET inhibition in cancer immunotherapy
$104,582Anjana Rao · La Jolla Institute For Immunology · R01 · FY2023 · CA
Pathogen Associated Malignancies
$104,511Denise A. Galloway · Fred Hutchinson Cancer Center · P30 · FY2025 · CA
MDSC-tumor crosstalk in prostate cancer progression and castration resistance
$104,445Guocan Wang · University Of Tx Md Anderson Can Ctr · K99 · FY2017 · CA
02 - Experimental Therapeutics
$104,387Narendra Wajapeyee · University Of Alabama At Birmingham · P30 · FY2024 · CA
02 - Experimental Therapeutics
$104,385Eddy Yang · University Of Alabama At Birmingham · P30 · FY2023 · CA
02 - Experimental Therapeutics
$104,385Eddy Yang · University Of Alabama At Birmingham · P30 · FY2022 · CA
Development of selective HDAC6 inhibitors to improve cancer immunotherapy
$104,326Alejandro V Villagra · George Washington University · R01 · FY2022 · CA
The replication checkpoint and genomic fidelity in skin
$104,220Massachusetts General Hospital · K02 · FY2004 · AR
P34CDC2 AND CELL CYCLE CONTROL
$104,095Washington University · R01 · FY2003 · GM
Angiopoietin-2/Tie2 signaling regulation of liver metastasis in pancreatic neuroendocrine tumors
$103,971Minah Kim · Columbia University Health Sciences · R37 · FY2023 · CA
Mitotic Mechanisms in Alzheimer's Disease
$103,667University Of British Columbia · R01 · FY2005 · AG
P3 - Mechanism-Based Use of Chk1 Inhibitors in Pancreas Cancer
$103,577Theodore S Lawrence · University Of Michigan At Ann Arbor · P50 · FY2012 · CA
Targeting BRD4 in Chronic Lymphocytic Leukemia (CLL) Disease Progression to Richter's Transformation (RT)
$103,394Dalia Elgamal · Ohio State University · K99 · FY2017 · CA
Targeting BRD4 in Chronic Lymphocytic Leukemia (CLL) Disease Progression to Richter's Transformation (RT)
$103,394Dalia Elgamal · Ohio State University · K99 · FY2016 · CA
TARGETING CCR2 TO OVERCOME IMMUNOSUPPRESSION AND IMPROVE IMMUNOTHERAPY
$102,843David G Denardo · Washington University · R21 · FY2015 · CA
BUBR1 in the Spindle Checkpoint and Tumor Suppression
$102,626New York University School Of Medicine · R01 · FY2005 · CA
Regulation of translation through the human translation initiation factor eIF5B
$102,600Assen G Marintchev · Boston University Medical Campus · K01 · FY2008 · CA
Emerging Immune Checkpoint Therapies Reshape the Cardiac Immune Landscape and Promote Myocardial Vulnerability
$102,495Pan Ma · Washington University · K99 · FY2024 · HL
Emerging Immune Checkpoint Therapies Reshape the Cardiac Immune Landscape and Promote Myocardial Vulnerability
$102,495Pan Ma · Washington University · K99 · FY2025 · HL
Evaluation of T follicular regulatory cells as novel cellular targets of cancer immunotherapy
$102,450Simon Eschweiler · La Jolla Institute For Immunology · R37 · FY2023 · CA